Viral Vectors

From Concept to Scale: Manufacturing Innovation

The use of viral transduction to introduce transgenes into specific cells, tissues, or organs has significantly advanced the fields of cell and gene therapy. However, realizing the full potential of this modality requires efficiently scaling up its manufacture.

Landmark Bio has established a robust infrastructure to support contemporary viral manufacturing needs through a strategic combination of hands-on expertise, investments in advanced technology, and agile partnership models.

Drug Development Services for Viral Vectors

Lentivirus

Comprehensive Support: for all stages of development from Benchtop R&D to cGMP Scale
- R&D Supply in 4-8 weeks with POSTmark^TM LVV
- GMP LVV 6-9 months with POSTmark^TM LVV
Integrated Capabilities: Streamlined processes to enable cell therapies such as CAR-T and CAR-NK, ensuring efficient timelines

Advanced Platforms: Optimization for 3rd and 4th generation LVV plasmid platforms with POSTmark^TM LVV
Solutions: In house transient & packaging lines
Quality Control & Fill/Finish: Full in-house capabilities for both small and large volumes.
Custom Packages: Specialized process and analytical development, including potency assay development

AAV

End-to-end Support: all stages of development from Benchtop R&D to cGMP Scale
- R&D Supply in 4-8 weeks with POSTmark^TM AAV
- GMP LVV AAV 6-9 months with POSTmark^TM AAV
In-house platform solution: Plug-and-play vector production with POSTmark^TM AAV

Quality Control & Fill/Finish: Full in-house capabilities for both small and large volumes.
Custom Packages: Specialized process and analytical development, including potency assay development

Novel Viruses

Leverage our advanced equipment, skilled personnel, and extensive experience for the development and production of novel viral vectors

Drug Development Services for Viral Vectors

Connect with an viral vector expert